KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Short term Debt (2018 - 2020)

Emergent BioSolutions has reported Short term Debt over the past 7 years, most recently at $22.3 million for Q2 2020.

  • For Q2 2020, Short term Debt fell 59.16% year-over-year to $22.3 million; the TTM value through Jun 2020 reached $22.3 million, down 59.16%, while the annual FY2019 figure was $3.2 million, 68.32% down from the prior year.
  • Short term Debt for Q2 2020 was $22.3 million at Emergent BioSolutions, up from $3.2 million in the prior quarter.
  • Over five years, Short term Debt peaked at $62.7 million in Q1 2019 and troughed at $3.2 million in Q4 2019.
  • A 3-year average of $27.2 million and a median of $16.2 million in 2018 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: tumbled 68.32% in 2019 and later crashed 59.16% in 2020.
  • Year by year, Short term Debt stood at $10.1 million in 2018, then tumbled by 68.32% to $3.2 million in 2019, then surged by 596.88% to $22.3 million in 2020.
  • Business Quant data shows Short term Debt for EBS at $22.3 million in Q2 2020, $3.2 million in Q4 2019, and $10.1 million in Q3 2019.